Metropolis Healthcare , a leading diagnostic services provider, has reported strong financial performance for the second quarter of fiscal year 2026 (Q2 FY26), demonstrating robust growth and strategic expansion initiatives.

Revenue Growth and Financial Highlights

Metropolis Healthcare delivered a consolidated revenue growth of approximately 23% year-on-year in Q2 FY26. This growth was primarily driven by the company's strong momentum in preventive health check-ups, particularly its TruHealth and wellness offerings. The company's performance remained resilient despite lower incidences of seasonal illnesses compared to the previous year.

Key financial highlights for Q2 FY26 include:

The company maintains a debt-free status, highlighting its strong financial position.

Margin Improvement and Operational Efficiency

Metropolis Healthcare reported improvements in its core diagnostics margins during the quarter. The company's subsidiary, Core Diagnostics, progressed from a breakeven position in Q4 FY25 to a high single-digit margin in Q2 FY26. This margin expansion is attributed to ongoing improvements in operational efficiency, operating leverage, and synergies.

At the consolidated level, Metropolis Healthcare's EBITDA margin remained strong, supported by operating leverage in the organic business and integration synergies at Core Diagnostics.

Strategic Expansion

In a significant move to enhance its regional presence, Metropolis Healthcare completed an acquisition in Kolhapur. The company acquired Dr. RS Patil's Ambika Pathology Laboratory, effective September 18, 2025. This strategic acquisition aims to:

1. Strengthen Metropolis Healthcare's leadership position in the Kolhapur region
2. Establish a mini reference laboratory to serve 4-5 surrounding districts in Western Maharashtra
3. Boost productivity and increase throughput
4. Reduce turnaround time (TAT) for diagnostic services

Segment Performance

The company's B2C and B2B segments both showed strong growth:

• B2C revenues grew by approximately 16% year-on-year
• B2B revenues increased by about 34%, driven by higher contributions from Core Diagnostics

Outlook

Metropolis Healthcare's management remains focused on ongoing margin increases and growth in wellness and specialty areas. The company's strategic initiatives, including regional expansions and operational improvements, are expected to contribute to its continued growth and market leadership in the diagnostic services sector.

As the company awaits the approval of its detailed financial results for Q2 FY26 by the Board of Directors, these preliminary figures indicate a positive trajectory for Metropolis Healthcare in the current fiscal year.

Metropolis Healthcare Limited (NSE: METROPOLIS, BSE: 542650) has successfully completed the acquisition of Dr. RS Patil's Ambika Pathology Laboratory, a sole proprietorship firm, as announced on September 18. This strategic move marks a significant expansion for the company in the pathology services sector.

Acquisition Details

The acquisition, which became effective on September 18, was executed as a going concern under the terms of a Business Transfer Agreement (BTA). Key points of the acquisition include:

• Ambika Pathology Laboratory, previously owned by Dr. Rajendra Sadashiv Patil, is now operating under Metropolis Healthcare Limited.
• The acquisition includes deferred consideration terms as outlined in the BTA.
• Operations of Ambika Pathology have been integrated into Metropolis Healthcare's business structure effective from the acquisition date.

Regulatory Compliance

In compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Metropolis Healthcare Limited disclosed the acquisition details to the stock exchanges. The company had previously intimated about this potential acquisition on August 07.

Management Statement

Kamlesh C Kulkarni, Head – Legal & Secretarial at Metropolis Healthcare Limited, confirmed the completion of the acquisition in a statement to the stock exchanges. He emphasized that the other terms and conditions, including the deferred consideration, will be carried out in accordance with the Business Transfer Agreement.

Market Impact

This acquisition is expected to strengthen Metropolis Healthcare's position in the pathology services market. By integrating Ambika Pathology Laboratory's operations, the company aims to expand its service offerings and geographical reach.